Thornburg Investment Management Inc. Invests $3.56 Million in Glaukos Co. (NYSE:GKOS)

Thornburg Investment Management Inc. purchased a new stake in Glaukos Co. (NYSE:GKOS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 30,103 shares of the medical instruments supplier's stock, valued at approximately $3,563,000. Thornburg Investment Management Inc. owned 0.06% of Glaukos as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. National Bank of Canada FI purchased a new stake in shares of Glaukos during the 4th quarter worth $46,000. Quadrant Capital Group LLC boosted its position in shares of Glaukos by 54.8% during the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier's stock worth $74,000 after acquiring an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. boosted its position in shares of Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier's stock worth $140,000 after acquiring an additional 1,465 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock valued at $141,000 after acquiring an additional 486 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC acquired a new stake in shares of Glaukos during the 2nd quarter worth about $187,000. Institutional investors and hedge funds own 99.04% of the company's stock.

Insider Activity

In related news, COO Joseph E. Gilliam sold 2,250 shares of Glaukos stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $121.39, for a total transaction of $273,127.50. Following the completion of the transaction, the chief operating officer now directly owns 101,845 shares in the company, valued at approximately $12,362,964.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now owns 30,119 shares of the company's stock, valued at approximately $3,614,280. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Joseph E. Gilliam sold 2,250 shares of Glaukos stock in a transaction on Friday, July 5th. The shares were sold at an average price of $121.39, for a total value of $273,127.50. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares of the company's stock, valued at approximately $12,362,964.55. The disclosure for this sale can be found here. Insiders sold a total of 41,500 shares of company stock worth $5,099,000 over the last 90 days. 6.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on GKOS shares. Stifel Nicolaus raised their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Morgan Stanley boosted their price target on shares of Glaukos from $100.00 to $120.00 and gave the company an "equal weight" rating in a research report on Monday, July 15th. Citigroup lowered Glaukos from a "buy" rating to a "neutral" rating and raised their price objective for the stock from $130.00 to $132.00 in a report on Wednesday, July 10th. StockNews.com downgraded Glaukos from a "hold" rating to a "sell" rating in a report on Friday, August 30th. Finally, Piper Sandler lifted their price target on Glaukos from $110.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Glaukos has a consensus rating of "Moderate Buy" and a consensus price target of $129.82.

Glaukos Stock Performance

NYSE GKOS traded up $0.01 during trading hours on Friday, hitting $126.28. 339,895 shares of the stock were exchanged, compared to its average volume of 583,850. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19. The company has a market cap of $6.94 billion, a price-to-earnings ratio of -43.76 and a beta of 1.03. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $136.60. The stock has a 50-day moving average of $124.45 and a 200 day moving average of $109.86.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.52). The business had revenue of $95.70 million during the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business's revenue was up 19.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.55) EPS. As a group, equities research analysts forecast that Glaukos Co. will post -2.18 earnings per share for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.